Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. BioInvent International AB's shares outstanding for the quarter that ended in Mar. 2026 was 65.80 Mil.
BioInvent International AB's quarterly shares outstanding
stayed the same
from Dec. 2025 (65.80 Mil) to Mar. 2026 (65.80 Mil).
BioInvent International AB's annual shares outstanding
stayed the same
from Dec. 2024 (65.80 Mil) to Dec. 2025 (65.80 Mil).
BioInvent International AB (OTCPK:BOVNF) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
BioInvent International AB Shares Outstanding (EOP) Related Terms
BioInvent International AB Shares Outstanding (EOP) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB Shares Outstanding (EOP) Chart
BOVNF vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, BioInvent International AB's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's Shares Outstanding (EOP) falls into.
BioInvent International AB Shares Outstanding (EOP) Calculation
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 65.80 Mil mean?
BioInvent International AB (BOVNF) has a Shares Outstanding (EOP) of 65.80 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on BioInvent International AB and its competitors.
Is BioInvent International AB's Shares Outstanding (EOP) too high?
BioInvent International AB's current Shares Outstanding (EOP) is 65.80 Mil. Overall, BioInvent International AB has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Shares Outstanding (EOP) compare to VRTX and REGN?
BioInvent International AB's Shares Outstanding (EOP) of 65.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Shares Outstanding (EOP) is 65.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current Shares Outstanding (EOP) of 65.80 Mil. The stock's GF Value™ is $6.77, compared to a current price of $3.29 — trading 51.4% below its estimated fair value. The current Shares Outstanding (EOP) is 65.80 Mil. BioInvent International AB's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current Shares Outstanding (EOP) is 65.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (BOVNF) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of $3.29 is trading 51.4% below its estimated GF Value™ of $6.77.
Key valuation signals for BOVNF:
Shares Outstanding (EOP): 65.80 Mil
GF Value™: $6.77 vs. price of $3.29 (51.4% below fair value)
No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
53GF Score
Get the complete analysis for BOVNF
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOVNF has been successfully added to your 
